BioNTech reports Q3 results, reconfirms FY guidance

by
Contributor since / Followers

3 weeks ago

BioNTech press release (NASDAQ:BNTX): Q3 GAAP EPS of €0.81
Revenue of €1.2B (+34.0% Y/Y).
Expects to be at low end of full year 2024 revenue guidance range (€2.5-3.1 billion)
Re-confirms guidance of planned full year 2024 R&D expenses of €2.4-2.6 billion and reduced guidance range for SG&A expenses to €600-700 million and for capital expenditures for operating activities to €300-400 million

Tags: BNTX